Fair Accountability and Innovative Research Drug Pricing Act of 2023
- Last Action
- 3/22/2023
Actions
- 2023-03-22Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2023-03-22Introduced in Senate
CRS Summary
As of 2023-03-22 (00)
Fair Accountability and Innovative Research Drug Pricing Act of 2023
This bill requires manufacturers to report about certain price increases for prescription drugs and biological products with a wholesale cost of at least $100 per month.
Such reports must include, among other information (1) the percentage price increase, (2) a justification for such increase, (3) the price history of the drug, (4) the total cost to develop the drug, and (5) the total revenue and net profit generated from the drug. Manufacturers are subject to civil penalties for failing to comply with the bill's requirements. Additionally, the Food and Drug Administration must post the information on its website.
Cosponsors (3)
- Mike Braun (R-IN)
- Tina Smith (D-MN)
- Martin Heinrich (D-NM)
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.